Prognostic Factors for Mortality in Patients With Autoimmune Diseases Complicated by Pneumocystis Pneumonia. (PubMed, Cureus) - Sep 25, 2024 - "Prophylactic administration of trimethoprim-sulfamethoxazole (TMP-SMX) was not performed in any of the cases. Additionally, the risk of mortality for PCP under the administration of new biological agents, such as anifrolumab, belimumab, and rituximab, or immunosuppressants, such as mycophenolate mofetil and voclosporin, should be evaluated. These findings can contribute to improving PCP prevention and treatment strategies in patients with autoimmune diseases, ultimately leading to better patient outcomes."
Biomarker • Journal • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammatory Arthritis • Pneumonia • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • CRP
|
|
Kunika Shimizu; Kuninobu Wakabayashi; Nobuyuki Yajima; Ryo Yanai; Takaaki Matsuyama; Yusuke Miwa
|